[Therapy of tparkinson's disease. Clinical and pharmacological viewpoints].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000547:Amantadine / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D009075:MSH Release-Inhibiting Hormone / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009127:Muscle Rigidity / Q000150:complications; D010276:Parasympatholytics / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D011187:Posture; D011605:Psychoses, Substance-Induced; D014202:Tremor / Q000150:complications
D000319:Adrenergic beta-Antagonists; D006634:Histamine H1 Antagonists; D008996:Monoamine Oxidase Inhibitors; D010276:Parasympatholytics; D001971:Bromocriptine; D007980:Levodopa; D009075:MSH Release-Inhibiting Hormone; D000547:Amantadine
Therapie der Parkinsonschen Krankheit. Klinische und pharmakologische Gesichtspunkte.